share_log

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(42.6%),The Tiger Cub Trust(38.6%)

SEC announcement ·  Jan 2 00:00
Summary by Moomoo AI
On December 28, 2023, Mangoceuticals, Inc. filed an amended Schedule 13D/A with the U.S. Securities and Exchange Commission, indicating a significant change in ownership by key figures. Jacob D. Cohen, the company's CEO and Chairman, and The Tiger Cub Trust reported a combined beneficial ownership of 9,775,000 shares of Mangoceuticals' common stock, representing 42.6% and 38.6% of the company respectively. This amendment follows the original Schedule 13D filed on May 3, 2023. The filing detailed the acquisition of shares by Jacob D. Cohen, which includes 1,500,000 shares with sole voting and dispositive power, and 8,275,000 shares with shared voting and dispositive power. The Tiger Cub Trust shares identical figures for shared voting and dispositive power. The filing also disclosed the grant of stock options to Cohen under the...Show More
On December 28, 2023, Mangoceuticals, Inc. filed an amended Schedule 13D/A with the U.S. Securities and Exchange Commission, indicating a significant change in ownership by key figures. Jacob D. Cohen, the company's CEO and Chairman, and The Tiger Cub Trust reported a combined beneficial ownership of 9,775,000 shares of Mangoceuticals' common stock, representing 42.6% and 38.6% of the company respectively. This amendment follows the original Schedule 13D filed on May 3, 2023. The filing detailed the acquisition of shares by Jacob D. Cohen, which includes 1,500,000 shares with sole voting and dispositive power, and 8,275,000 shares with shared voting and dispositive power. The Tiger Cub Trust shares identical figures for shared voting and dispositive power. The filing also disclosed the grant of stock options to Cohen under the company's 2022 Equity Incentive Plan, which vested immediately upon grant. The options, exercisable at prices of $0.32 and $1.10 per share, are set to expire in 2028 and 2027 respectively. The reporting persons have stated that the securities were acquired for investment purposes and may buy or sell additional securities depending on market conditions. No plans for major corporate changes or transactions were disclosed at this time.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more